MIDOSTAURIN

Midostaurin is an anticancer medication that was approved for medical use in April 2017.

Midostaurin is a prescription medicine developed to treat acute myeloid leukemia caused by a mutation in FLT3 genes. It is also indicated to treat aggressive system mast cytosis, systemic mast cytosis with hematological neoplasm, and mast cell leukemia.

Midostaurin is available in form of Capsules in the dose 25mg. The usual recommended dosing is 50mg twice daily with food for acute myeloid leukemia and 100mg twice daily for aggressive systemic mast cytosis and systemic mast cytosis. Swallow Midostaurin Capsule whole with a glass of water.

The common side effects that are likely to occur while you are on the treatment with Midostaurin Capsule are nausea, vomiting, diarrhoea, tiredness, constipation, nose bleeds, muscle or bone pain, upper respiratory tract infection, bruising, mouth ulcers, headache, fever, trouble breathing, high blood sugar levels, stomach pain, swelling of hands and feet. If you experience any allergic reactions or any other symptoms like shortness of breath, chills, or swelling, report to your doctor immediately.

Midostaurin not recommended for patients who are allergic to Midostaurin, or its ingredients. It is essential to let your physician know if you are diagnosed with problems in your kidneys or liver. Your physician will regularly monitor your blood cell count, blood pressure, cholesterol, liver and kidney parameters to prevent complications. Seek immediate medical attention if you experience worsening cough, chest discomfort or shortness of breath.

Midostaurin can affect the fertility of male and female patients. Female patients and female partners of male patients should avoid getting pregnant during this treatment. Tell your healthcare provider if you are pregnant, think you might be pregnant, breastfeeding or planning to have a baby. Discuss effective contraceptive methods with your healthcare practitioner and continue using birth control methods for 4 months after the final dose of Midostaurin. Do not breastfeed during and 4 months after the last dose of Midostaurin capsule.

Avoid driving and operating machinery while receiving Midostaurin treatment if dizziness occurs. Your doctor will prescribe medications to manage nausea and vomiting associated with Midostaurin therapy.

Novartis, US Food & Drug Administration, [Revised on Nov 2021] [Accessed on 25th Oct 2022], https://www.novartis.com/us-en/sites/novartis_us/files/rydapt.pdf Anton Wellstein, Giuseppe Giaccone, Michael B. Atkins, and Edward A. Sausville, Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules, Goodman & Gilman’s Pharmacological Basis of Therapeutics, 13th Edition, 2018, 1203-1236.